PBAC's latest decision on Patiromer: Recommended with restriction (2023). Considered for Initial treatment of adult patients with chronic kidney disease (CKD) Stage 3-4, with chronic hyperkalaemia (at least two episodes of serum potassium 6.0 mmol/L or higher in the previous 12 months), who are receiving at least one renin angiotensin aldosterone system inhibitor (RAASi) medicine or are indicated for a RAASi medicine but are unable to tolerate it due to prior occurrence of hyperkalaemia.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2019
Submissions
4
2019 → 2023
Eligible population
Adults with chronic kidney disease Stage 3-4, chronic hyperkalaemia (at least 2 episodes of serum potassium ≥6.0 mmol/L in previous 12 months), receiving or indicated for RAASi but unable to tolerate due to prior hyperkalaemia.
Therapy area
Endocrinology
Line of therapy
First-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
sodium polystyrene sulfonate (SPS) and calcium polystyrene sulfonate (CPS)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. PBAC advised that cost-utility analysis was unreliable and a cost-minimisation approach versus SPS/CPS resins was appropriate.
Risk sharing
Risk-sharing arrangement in place — Risk sharing arrangement presented based on revised financial estimates with expenditure caps beyond which a rebate of % was applied.
Submission history
Nov 2019: Not recommended · Authority Required
Nov 2020: Recommended with restriction · Authority Required
Nov 2022: Recommended with restriction · Authority Required
Mar 2023: Recommended with restriction · Authority Required